ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,918.25
      0.00%
      US Tech 100
      20,622.00
      0.05%
      Dow Jones
      42,635.20
      0.00%
      Brent Oil
      78.845
      2.50%
      Bitcoin
      94,696.97
      2.47%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Germany
      5. TG

      6. Genmab AS (GE9) Quote

      Genmab AS

      Genmab AS (GE9)

      TG
      214.00
      -1.30
      ( -0.60% )
      Updated: 06:30:00
      Realtime Data

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      214.00
      Bid
      214.50
      Ask
      214.60
      Volume
      8
      214.00 Day's Range 214.80
      188.60 52 Week Range 297.10
      Market Cap
      14.058B
      Previous Close
      215.30
      Open
      214.80
      Last Trade
      5
      @
      214
      Last Trade Time
      04:07:06
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      329
      Shares Outstanding
      65,691,573
      Dividend Yield
      -
      PE Ratio
      3.33
      Earnings Per Share (EPS)
      66.25
      Revenue
      16.47B
      Net Profit
      4.35B

      About Genmab AS

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biogenetic (human)
      Website
      www.genmab.com
      Headquarters
      Copenhagen, Dnk
      Founded
      2000
      Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 215.30 €. Over the last year, Genmab AS shares have traded in a share price range of 188.60 € to 297.10 €.

      Genmab AS currently has 65,691,573 shares outstanding. The market capitalization of Genmab AS is 14.14 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 3.33.

      Ask ADVFN Intelligence (AI)

      GE9 Latest News

      More News

      FeaturedCannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology

      22 hours ago

      Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel...

      January 03 2025
      UK Regulatory

      Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

      Genmab to Hold 2024 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 –...

      December 11 2024
      UK Regulatory

      Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

      Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell...

      December 09 2024
      UK Regulatory

      Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

      Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic...

      December 08 2024
      UK Regulatory

      Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

      Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Media...

      December 07 2024
      UK Regulatory

      Capital Increase in Genmab as a Result of Employee Warrant Exercise

      Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by...

      December 03 2024
      UK Regulatory

      Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

      Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab...

      December 03 2024
      UK Regulatory

      Genmab to Present at Citi’s Global Healthcare Conference

      Genmab to Present at Citi’s Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony...

      November 25 2024
      UK Regulatory

      Grant of Restricted Stock Units and Warrants to Employees in Genmab

      Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided...

      November 21 2024
      UK Regulatory
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      18.54.13625304136205.5216.9204.8174212.10412844DE
      412.96.41471904525201.1216.9188.6304199.64694146DE
      1231.42180094787211223188.6329204.87149458DE
      26-22.3-9.43715615743236.3264.7188.6283219.61347365DE
      52-80-27.2108843537294297.1188.6227235.19990898DE
      156-110.3-34.0117175455324.3362.9188.6176245.34302695DE
      260-159.6-42.7194860814373.6374.3188.6164245.63604498DE

      GE9 - Frequently Asked Questions (FAQ)

      What is the current Genmab AS share price?
      The current share price of Genmab AS is 214.00 €
      How many Genmab AS shares are in issue?
      Genmab AS has 65,691,573 shares in issue
      What is the market cap of Genmab AS?
      The market capitalisation of Genmab AS is EUR 14.14B
      What is the 1 year trading range for Genmab AS share price?
      Genmab AS has traded in the range of 188.60 € to 297.10 € during the past year
      What is the PE ratio of Genmab AS?
      The price to earnings ratio of Genmab AS is 3.33
      What is the cash to sales ratio of Genmab AS?
      The cash to sales ratio of Genmab AS is 0.88
      What is the reporting currency for Genmab AS?
      Genmab AS reports financial results in DKK
      What is the latest annual turnover for Genmab AS?
      The latest annual turnover of Genmab AS is DKK 16.47B
      What is the latest annual profit for Genmab AS?
      The latest annual profit of Genmab AS is DKK 4.35B
      What is the registered address of Genmab AS?
      The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260
      What is the Genmab AS website address?
      The website address for Genmab AS is www.genmab.com
      Which industry sector does Genmab AS operate in?
      Genmab AS operates in the BIOGENETIC (HUMAN) sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      L7C2Windfall Geotek Inc
      0.0145 €
      (70.59%)
      		276
      7KOCullinan Metals Corp
      0.0166 €
      (59.62%)
      		100k
      E3O1Nexoptic Technology Corp
      0.0265 €
      (39.47%)
      		1.53k
      M11First Graphene Limited
      0.0298 €
      (26.27%)
      		728.52k
      YP2ABioline Rx Ltd
      0.171 €
      (23.91%)
      		10k
      1K0IGM Biosciences Inc
      1.88 €
      (-62.40%)
      		291
      POTAPortofino Resources Inc
      0.0028 €
      (-46.15%)
      		35k
      36WWeimob Inc
      0.23 €
      (-42.21%)
      		1,000
      UH7ATennant Minerals NL
      0.0045 €
      (-40.00%)
      		20.92k
      CNWCodon AG
      0.007 €
      (-36.36%)
      		11.87k
      PF8European Lithium Limited
      0.034 €
      (3.66%)
      		2.16M
      D7GNel ASA
      0.2498 €
      (-1.65%)
      		864.88k
      LHADeutsche Lufthansa AG
      5.616 €
      (-0.35%)
      		840.65k
      G7PAEnergy Transition Minerals Ltd
      0.0472 €
      (4.89%)
      		770.96k
      EOANE. On SE
      10.825 €
      (-2.43%)
      		768.35k

      Discussion

      View Full Feed
      adesell adesell 5 minutes ago
      Guess we can all admit we are screwed now? I mean, the Canadian Tuxedo TRT crew that runs scam hasn't even said a word in many months. You figure they would at least try to dangle the carrot again but nope...nothing. However Prodigy Health wishes you a Happy holidays on social media, that really hel
      TRT
      capgain capgain 5 minutes ago
      There's no excuse for what their so called leaders have done.
      powerwalker powerwalker 5 minutes ago
      3jack, here is ihidfromtheX's personal email. He beat cancer and it took several years. He is a good guy and willing to help.

      Thank you, ihidfromtheX!!! 👍️👏
      AVXL
      capgain capgain 6 minutes ago
      Happy Birthday, Red.
      glenn1919 glenn1919 7 minutes ago
      MRSN.................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
      MRSN
      diggitydoodle diggitydoodle 8 minutes ago
      FOXO is headed back to .20.
      RNVA is stuck at worthless.
      Well, let's see if a $1+ million judgment against RNVA helps this ticker to finally WAKE UP.
      GLTA.
      RNVA!!$$???????????????????
      FOXO RNVA
      glenn1919 glenn1919 9 minutes ago
      BER....CGBS.....STAI.....VRME.....https://stockcharts.com/h-sc/ui?s=VRME&p=W&yr=1&mn=3&dy=0&id=p96837884856
      CGBS STAI VRME
      glenn1919 glenn1919 10 minutes ago
      ZVSA.....VMAR......MCVT.......FPAY......https://stockcharts.com/h-sc/ui?s=FPAY&p=W&yr=1&mn=3&dy=0&id=p96837884856
      FPAY MCVT VMAR
      glenn1919 glenn1919 10 minutes ago
      DBVT.....SLDP......CNTX.......................https://stockcharts.com/h-sc/ui?s=DBVT&p=W&yr=1&mn=3&dy=0&id=p96837884856
      CNTX DBVT SLDP
      Just the facts maam Just the facts maam 13 minutes ago
      Silvr, something interesting regarding patent application # 13/135,999.

      It had a child. patent application # 15/288,511, which has never been published. It was filed 10/07/2016 and was subsequently abandoned. When I query # 15/288,511 this is the response I get.

      Sor
      ANIP
      tradero tradero 14 minutes ago
      Tier's 1 are still very interested. And it seems that ML was a real obstacle in the process, or maybe it was having abandoned the path of making full PICs in house that mattered. Anyway, discussions are ongoing

      From YL:
      LWLG
      glenn1919 glenn1919 14 minutes ago
      ZCAR.................SMX......................WATT..........................https://stockcharts.com/h-sc/ui?s=WATT&p=W&yr=1&mn=3&dy=0&id=p96837884856
      SMX ZCAR
      infamous infamous 15 minutes ago
      someone should write a movie...ILAL The Makings of a 000 stock in blueray and 3d
      ILAL
      Konaploinks Konaploinks 17 minutes ago
      Up 4 bucks pre market. The truth is getting out. Finally. But So far no help from our corporation . This is not the great leadership I thought we had. Even if he says something now it will be too late. It’s never good to be goaded into something. That’s not Celina leader. The guy from D wave. Now he
      IONQ
      Iggy_Bot Iggy_Bot 18 minutes ago
      Happy Birthday 🎂
      trader53 trader53 18 minutes ago
      WCVC Has until Jan 31, 2025 to Submit Application

      Companies have until January 31 to submit the application

      Pink Current become OTCID July 1, 2025

      https://www.securitieslawyer101.com/2025/pink-current-will-become-otcid/

      https://investorshub
      Konaploinks Konaploinks 18 minutes ago
      Up 4 bucks pre market. The truth is getting out. Finally. But So far no help from our corporation . This is not the great leadership I thought we had. Even if he says something now it will be too late. It’s never good to be goaded into something. That’s not Celina leader. The guy from D wave. Now he
      IONQ
      microchips microchips 18 minutes ago
      That was a lot of work for a bunch of gibberish.
      LWLG
      ohsaycanyousee82 ohsaycanyousee82 20 minutes ago
      “Even if EMA approves the current submission, a new confirmatory trial will still be required to expand the label.”

      To which all shareholders will do a collective YAWN.
      AVXL
      Iggy_Bot Iggy_Bot 20 minutes ago
      Can't wait till the Days read 0 Hours read 0 Minutes read 0..
      tradero tradero 20 minutes ago
      Jeunke, are you sure about that? It is not that it really matters as it would only bring very limited revenue but this is what YL said yesterday:

      LWLG
      MasterBlastr MasterBlastr 21 minutes ago
      Nice going, Red! A while back I started celebrating half-birthdays, just in case.
      Polymer Paul Polymer Paul 24 minutes ago
      Here he is .... The ihub lebby!!!! Your breadcrumb post ...and that's what it is ... Ain't gonna stop today's huge selloff. Do everyone a favour. Disappear like lebby !!!!
      LWLG
      Lurker3 Lurker3 25 minutes ago
      Here is a message I shared with my friends

      And you received: Failed to deliver
      LWLG
      trader53 trader53 26 minutes ago
      DPLS Pink Current become OTCID July 1, 2025

      Companies have until January 31 to submit the application

      https://www.securitieslawyer101.com/2025/pink-current-will-become-otcid/

      DPLS - Has been approved for OTCID
      https://investorshub.advfn.com/b
      DPLS OTCID

      Your Recent History

      TG
      GE9
      Genmab AS
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads